The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Drug: Any drug used to treat Covid-19
lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
Inclusion Criteria:
- all patients treated for Covid-19
Exclusion Criteria:
- Chronology not compatible between the drug and the toxicity
AP-HP Assistance Publique Hopitaux de Paris
Paris, France
Joe-Elie Salem, MD, PhD, Study Director
Clinical Investigations Center